MoleculeMind Raises Over $100M in Series A to Expand AI Protein Design Infrastructure
MoleculeMind, an AI protein design platform, has completed a Series A funding round totaling over $100M from investors including Bluebridge Capital, Pudong Venture Capital, COFCO Emerging Industry Fund, and others, with existing investors like Cathay Biotech also participating. The company unveiled MMDesign, an AI-driven de novo antibody design platform that achieved over 90% target hit rate on 12 real clinical targets and delivered picomolar-level affinity against the challenging TNFα target after testing only 14–50 AI-designed candidates. Its proprietary MMFold structure prediction engine outperforms Google AlphaFold 3 and all open-source models on the FoldBench antibody-antigen interface benchmark. MoleculeMind has built MoleculeOS, an AI-native protein engineering infrastructure based on its NewOrigin multimodal foundational model, which has been validated in industrial collaborations across drug discovery, green biomanufacturing, and novel materials. The company has established multi-layer commercial partnerships with top global pharma, synthetic biology firms, and chemical groups, demonstrating strong product-market fit and creating a closed-loop data flywheel from wet-lab-verified projects.